NasdaqCM:ZYXI

Stock Analysis Report

Executive Summary

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • Zynex has significant price volatility in the past 3 months.
  • Zynex is covered by less than 3 analysts.

Share Price & News

How has Zynex's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.0%

ZYXI

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

222.3%

ZYXI

9.7%

US Medical Equipment

0.7%

US Market

ZYXI outperformed the Medical Equipment industry which returned 9.9% over the past year.

ZYXI outperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

ZYXIIndustryMarket
7 Day11.0%1.2%-0.6%
30 Day8.6%3.5%4.9%
90 Day-14.8%3.2%1.7%
1 Year231.0%222.3%10.6%9.7%3.0%0.7%
3 Year4786.2%4657.1%70.6%65.4%44.8%35.4%
5 Year7218.8%7025.5%139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Zynex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zynex undervalued based on future cash flows and its price relative to the stock market?

18%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Zynex's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Zynex's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Zynex is good value based on earnings compared to the US Medical Equipment industry average.

Zynex is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Zynex is poor value based on expected growth next year.


Price Based on Value of Assets

Zynex is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Zynex expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

23.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Zynex's revenue is expected to grow significantly at over 20% yearly.

Zynex's earnings are expected to grow significantly at over 20% yearly.

Zynex's revenue growth is expected to exceed the United States of America market average.

Zynex's earnings growth is expected to exceed the United States of America market average.

Zynex's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Zynex will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Zynex performed over the past 5 years?

76.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Zynex has delivered over 20% year on year earnings growth in the past 5 years.

Zynex's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Zynex's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

Zynex made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

Zynex used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Unable to establish if Zynex improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.


Next Steps

Financial Health

How is Zynex's financial position?


Financial Position Analysis

Zynex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Zynex's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Zynex has no debt.

Zynex currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Zynex has no debt, it does not need to be covered by operating cash flow.

Zynex has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Zynex has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Zynex's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Zynex's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Zynex's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Zynex has not reported any payouts.

Unable to verify if Zynex's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Zynex has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Zynex's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

Thomas Sandgaard (60yo)

23.7yrs

Tenure

US$1,085,475

Compensation

Mr. Thomas Sandgaard founded Zynex, Inc. in 1996 and has been its Chairman, Chief Executive Officer and President since 1996. Mr. Sandgaard served as the Chief Financial Officer and Chief Accounting Office ...


CEO Compensation Analysis

Thomas's remuneration is lower than average for companies of similar size in United States of America.

Thomas's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.


Management Age and Tenure

1.4yrs

Average Tenure

The average tenure for the Zynex management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.7yrs

Average Tenure

60.5yo

Average Age

The average tenure for the Zynex board of directors is less than 3 years, this suggests a new board.


Insider Trading

Zynex individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$1,038,00020 Aug 19
Thomas Sandgaard
EntityIndividual
Role
Chief Executive Officer
Founder
Shares100,000
Max PriceUS$10.38
SellUS$30,93812 Jun 19
Daniel Moorhead
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares3,750
Max PriceUS$8.25
SellUS$1,844,02507 Jun 19
Thomas Sandgaard
EntityIndividual
Role
Chief Executive Officer
Founder
Shares218,000
Max PriceUS$8.57
SellUS$179,15314 May 19
Daniel Moorhead
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares25,000
Max PriceUS$7.24
SellUS$211,46221 Mar 19
Thomas Sandgaard
EntityIndividual
Role
Chief Executive Officer
Founder
Shares48,008
Max PriceUS$4.41

Ownership Breakdown


Management Team

  • Thomas Sandgaard (60yo)

    Founder

    • Tenure: 23.7yrs
    • Compensation: US$1.09m
  • Chris Brown

    Vice President of Sales & Marketing

    • Tenure: 0.6yrs
  • Dan Moorhead (47yo)

    Chief Financial Officer

    • Tenure: 2.3yrs
    • Compensation: US$404.18k
  • Joachim Sandgaard

    Information Systems Manager

    • Tenure: 0yrs
    • Compensation: US$92.00k
  • Giuseppe Papandrea

    Chief Operating Officer

    • Tenure: 0.2yrs

Board Members

  • Barry Michaels (69yo)

    Director

    • Tenure: 1.7yrs
    • Compensation: US$116.25k
  • Thomas Sandgaard (60yo)

    Founder

    • Tenure: 23.7yrs
    • Compensation: US$1.09m
  • Michael Cress (61yo)

    Director

    • Tenure: 1.7yrs
    • Compensation: US$106.52k
  • Josh Disbrow (44yo)

    Independent Director

    • Tenure: 1.5yrs
    • Compensation: US$113.08k

Company Information

Zynex, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zynex, Inc.
  • Ticker: ZYXI
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$324.256m
  • Shares outstanding: 32.46m
  • Website: https://www.zynex.com

Number of Employees


Location

  • Zynex, Inc.
  • 9555 Maroon Circle
  • Englewood
  • Colorado
  • 80112
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZYXINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2004

Biography

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stim ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 23:55
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.